… 884 patients were analysable for PFS; 437 in the erlotinib … After a median follow-up of 11·4
months for the erlotinib group … with erlotinib than with placebo: 12·3 weeks for patients in the …

… The potential for combining EGFR TKIs with cytotoxic drugs was initially investigated in four
randomized phase III trials. In these studies, concurrent administration of erlotinib or gefitinib …

… to erlotinib in patients with lung adenocarcinoma. To evaluate the toxicity and efficacy of …
and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II …

… for erlotinib, which extended to the subgroup of patients with PS 2 and 3. On the basis of these
observations, we conducted a randomized phase … of advanced NSCLC patients with PS 2. …

… of erlotinib. The Cancer and Leukemia Group B trial 30406 was a randomized phase 2
clinical trial that investigated erlotinib alone or with carboplatin and paclitaxel in patients with a …

Purpose Epidermal growth factor receptor (EGFR) –tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

… We conducted this international, randomized phase II trial to prospectively … of erlotinib plus
tivantinib with erlotinib plus placebo among previously treated, EGFR inhibitor–naive patients …

… In summary, in this global, randomized, phase III trial in patients with NSCLC previously …
plus erlotinib resulted in greater ORR and longer PFS compared with placebo plus erlotinib but …

… Patients were stratified by EGFR mutation type, ECOG PS, gender, and country. … , erlotinib
patients could crossover to receive GP and GP patients could crossover to receive erlotinib. All …

… We conducted a global, randomized, placebo-controlled, phase II study in patients with
recurrent NSCLC evaluating onartuzumab plus erlotinib versus placebo plus erlotinib. Patients …